1. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. (February 2017) Authors: Singh, Jasmeet C.; Mamtani, Anita; Barrio, Andrea; Morrow, Monica; Sugarman, Steven; Jones, Lee W.; Yu, Anthony F.; Argolo, Daniel; Smyth, Lilian M.; Modi, Shanu; Schweber, Sarah; Boafo, Camilla; Patil, Sujata; Norton, Larry; Baselga, Jose; Hudis, Clifford A.; Dang, Chau Journal: Oncologist Issue: Volume 22:Number 2(2017) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. (18th September 2017) Authors: Singh, Jasmeet C.; Mamtani, Anita; Barrio, Andrea; Morrow, Monica; Sugarman, Steven; Jones, Lee W.; Yu, Anthony F.; Argolo, Daniel; Smyth, Lilian M.; Modi, Shanu; Schweber, Sarah; Boafo, Camilla; Patil, Sujata; Norton, Larry; Baselga, Jose; Hudis, Clifford A.; Dang, Chau Journal: Oncologist Issue: Volume 22:Number 2(2017) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗